<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":1246,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Dey Pharma, LP v. Sunovion Pharmaceuticals, Inc., 677 F.3d 1158, 102 U.S.P.Q.2d 1710 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/8aa6afcb6c93e1fd566e4a7344efbc84'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/8aa6afcb6c93e1fd566e4a7344efbc84'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1HF8Q0003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HF8Q0003">Previous Result: <span>Bertolo v. Benezee, Civil Action No. 11-...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1HF8Q4003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HF8Q4003">Next Result: <span>United States v. Grosinske, Criminal Cas...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='Dey Pharma, LP v. Sunovion Pharmaceuticals, Inc., 677 F.3d 1158, 102 U.S.P.Q.2d 1710 (Fed. Cir. 2012), Court Opinion'>
Dey Pharma, LP v. Sunovion Pharmaceuticals, Inc., 677 F.3d 1158, 102 U.S.P.Q.2d 1710 (Fed. Cir....
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Dey Pharma, LP v. Sunovion Pharmaceuticals, Inc., 677 F.3d 1158, 102 U.S.P.Q.2d 1710 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1HF6KE003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Dey Pharma, LP v. Sunovion Pharmaceuticals, Inc.</div>
<div class='displayCitation'>102 U.S.P.Q.2d 1710</div>
<div class='displayCitation'>2012 BL 92045</div>
<div class='displayCitation'>2012 BL 94728</div>
<div class='displayCitation'>677 F.3d 1158</div>
<div class='displayCitation'>bna a0d1m7n4q4</div>
<div class='displayCitation'>bna a0d2n4m2q0</div>
<div class='displayCitation'>wkffecase:25939271</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HF6KE003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Dey Pharma, LP v. Sunovion Pharmaceuticals, Inc., 677 F.3d 1158, 102 U.S.P.Q.2d 1710 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Dey Pharma, LP v. Sunovion Pharmaceuticals, Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1HF6KE003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HF6KE003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HF6KE003" /><input id="title" name="title" type="hidden" value="Dey Pharma, LP v. Sunovion Pharmaceuticals, Inc., 677 F.3d 1158, 102 U.S.P.Q.2d 1710 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="8aa6afcb6c93e1fd566e4a7344efbc84" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HF6KE003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%38aa%36afcb%36c%39%33e%31fd%35%36%36e%34a%37%33%34%34efbc%38%34%2Fdocument%2FX%31HF%36KE%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/bcite/X1HF6KE003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/bcite/X1HF6KE003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/bcite/X1HF6KE003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/related_content/X1HF6KE003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1699956064259";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">677 F.3d 1158</div>
<div class="cite" data-cite-type="ReporterOfDecisions">102 U.S.P.Q.2d 1710</div>
<div class="cite" data-cite-type="DocketNumber">2011-1507</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 94728</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
DEY PHARMA, LP and Dey Inc., Plaintiffs-Appellees, v. SUNOVION
PHARMACEUTICALS INC., Defendant-Appellant.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 2011-1507.
</center></p>
<p><center>
April 16, 2012.
<span CLASS="page_no" data-cite="102 uspq 2d 1711" data-cite-type="ReporterOfDecisions" data-cite-pageno="1711" data-primary-citation="102 U.S.P.Q.2d 1710">[**1711]</span> </center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">JUDICIAL PRACTICE AND PROCEDURE</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914970" href="#headnote_ref_pq2-dec_914970">[1]</a> <span>Jurisdiction &mdash; Subject matter jurisdiction &mdash;
Case or controversy </span> <a href="http://www.bloomberglaw.com/document/1699956064259/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=405.0703" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="405.0703">&#9658;405.0703</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnoteSlug">REMEDIES</div>
<div class="headnoteDescriptor">
<span>Non-monetary and injunctive &mdash; Declaratory judgments </span> <a href="http://www.bloomberglaw.com/document/1699956064259/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=505.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="505.05">&#9658;505.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Subject matter jurisdiction existed at time plaintiffs filed suit for declaratory judgment of invalidity and noninfringement of defendant's last-expiring patent relating to drug approved by U.S. Food and Drug Administration, since plaintiffs, who are second filers of abbreviated new drug application for generic version of approved drug, did not stipulate to infringement and validity of defendant's first-expiring patents, since plaintiffs brought suit after defendant sued for infringement of first-expiring patents only, since plaintiffs allege they are being excluded from selling noninfringing product, and since this alleged injury is &ldquo;fairly traceable&rdquo; to defendant and is redressible by declaratory judgment that patent in suit is not infringed, in that such judgment will eliminate potential for patent to exclude plaintiffs from market, and they would then need only judgment of invalidity or noninfringement on first-expiring patents to trigger first ANDA filer's 180-day exclusivity period;
eliminating one barrier to market entry is sufficient for declaratory jurisdiction, provided litigation is also pending that could eliminate other barriers.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">JUDICIAL PRACTICE AND PROCEDURE</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914971" href="#headnote_ref_pq2-dec_914971">[2]</a> <span>Jurisdiction &mdash; Subject matter jurisdiction &mdash;
Case or controversy </span> <a href="http://www.bloomberglaw.com/document/1699956064259/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=405.0703" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="405.0703">&#9658;405.0703</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Procedure &mdash; Moot controversies </span> <a href="http://www.bloomberglaw.com/document/1699956064259/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.12" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.12">&#9658;410.12</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnoteSlug">REMEDIES</div>
<div class="headnoteDescriptor">
<span>Non-monetary and injunctive &mdash; Declaratory judgments </span> <a href="http://www.bloomberglaw.com/document/1699956064259/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=505.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="505.05">&#9658;505.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnote_text">
Subject matter jurisdiction exists over action, brought by second filers of abbreviated new drug application, for declaratory judgment of invalidity and noninfringement of defendant's last-expiring patent relating to drug approved by U.S. Food and Drug Administration, even if it is assumed that separate litigation over first-expiring patents relating to drug cannot be concluded by final judgment before first ANDA filer is entitled to launch its generic product, and that resolution of that litigation is necessary to trigger first ANDA filer's 180-day exclusivity period, since, even after first ANDA filer is entitled to launch, possibility remains that it will not do so, and if first ANDA filer chooses to delay triggering exclusivity period, plaintiffs could potentially be kept off market until expiration of patent in suit, absent judgment of noninfringement or invalidity, and since case or controversy necessary to support declaratory judgment jurisdiction thus will not disappear simply because period of possible first generic market entry arrives; subject matter jurisdiction existed at time plaintiffs filed action, and defendant, which has conceded that case will not be moot until first ANDA filer goes on market in manner that would trigger its exclusivity period, has not met &ldquo;heavy burden&rdquo; of persuading court that case has become moot.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the District of Delaware,
Leonard P. Stark, J.
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span CLASS="page_no" data-cite="677 f 3d 1159" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1159" data-primary-citation="677 F.3d 1158">[*1159]</span> 
Elizabeth A. Leff, Frommer Lawrence &amp; Haug LLP, of Washington, DC, argued
for plaintiffs-appellees. With her on the brief were Edgar H. Haug and Sam
V. Desai, of New York, NY.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Eric W. Dittmann, Paul Hastings, LLP, of New York, NY, argued for
defendant-appellant. With him on the brief were Joseph M. O'Malley, Jr.,
Bruce M. Wexler and Preston K. Ratliff, II; Stephen B. Kinnaird, of
Washington, DC.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before BRYSON, DYK, and MOORE, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
DYK, Circuit Judge.
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dey Pharma, LP and Dey Inc. ("Dey") brought suit against Sunovion
Pharmaceuticals, Inc. ("Sunovion") seeking a declaratory judgment that Dey's
generic pharmaceutical product does not infringe Sunovion's U.S. Patent No.
<cite>6,451,289</cite> ("the '289 patent"), and that the '289 patent is invalid. The
district court concluded that it had subject-matter jurisdiction over the
action, and the parties thereafter stipulated to a final judgment of
noninfringement. <i>See Dey Pharma, L.P. v. Sunovion Pharms. Inc.</i>, <cite>No. 08-372</cite>
(D.Del. June 20, 2011) (final judgment); <i>Dey LP v. Sepracor Inc.</i>, <cite>No.
08-372</cite>, [<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1Q6L4UJ7HO2?jcsearch=2009%20BL%2081765&amp;summary=yes#jcite">2009 BL 81765</a>], 2009 WL 1043892 (D.Del. Apr. 16, 2009) (denying motion for
certification); <i>Dey, L.P. v. Sepracor, Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1AGEJ0003?jcsearch=595%20f%20supp%202d%20355&amp;summary=yes#jcite">595 F.Supp.2d 355</a> (D.Del. 2009)
(denying motion to dismiss).<a HREF="#fn100" name="fnref_fn100">[fn1]</a> Sunovion appeals, challenging the district
court's subject-matter jurisdiction. We affirm.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This declaratory judgment action involves the Drug Price Competition and
Patent Term Restoration Act of 1984, Pub.L. No. <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=USACTS%2098-117&amp;summary=yes#jcite">98-117</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=98%20stat%201585&amp;summary=yes#jcite">98 Stat. 1585</a>
("Hatch-Waxman Act"), in which "Congress struck a balance between two
competing policy interests: (1) inducing pioneering research and development
of new drugs and (2) enabling competitors to bring low-cost, generic copies
of those drugs to market," <i>Andrx Pharms., Inc. v. Biovail Corp.</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XAFMO2?jcsearch=276%20f%203d%201368&amp;summary=yes#jcite">276 F.3d 1368</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XAFMO2?jcsearch=276%20f%203d%201368&amp;summary=yes#jcite">1371</a> (Fed.Cir.2002). Under the Hatch-Waxman framework, a
brand-name company seeking FDA approval of a new drug must file <span CLASS="page_no" data-cite="102 uspq 2d 1712" data-cite-type="ReporterOfDecisions" data-cite-pageno="1712" data-primary-citation="102 U.S.P.Q.2d 1710">[**1712]</span> a new drug
application ("NDA") with the Food and Drug Administration ("FDA"), which
must include information about patents "with respect to which a claim of
patent infringement could reasonably be asserted." <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(b)(1).
The FDA publishes this patent information, <i>see <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XAFMO2?jcsearch=276%20F.3d%201368&amp;summary=yes#jcite">id</a>.</i>, in a publication known
as the "Orange Book."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A generic company may then seek FDA approval using an abbreviated new drug
application ("ANDA") with a certification for each patent in the Orange
Book, such as a "paragraph III certification" (that approval is not sought
until the patent expires) or a "paragraph IV certification" ("that such
patent is invalid or will not be infringed"). <i><cite>Id</cite>.</i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(vii)&amp;summary=yes#jcite">&sect; 355(j)(2)(A)(vii)</a>. If an
<span CLASS="page_no" data-cite="677 f 3d 1160" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1160" data-primary-citation="677 F.3d 1158">[*1160]</span> 
ANDA contains only paragraph IV certifications, the ANDA may be approved
unless the NDA holder sues the ANDA filer for patent infringement within 45
days. <i>See <cite>id</cite>.</i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(g)(5)(b)(iii)&amp;summary=yes#jcite">&sect; 355G)(5)(B)(iii)</a>.<a HREF="#fn200" name="fnref_fn200">[fn2]</a> The first generic company to file an
ANDA containing a paragraph IV certification receives a 180-day exclusivity
period from the date of its "first commercial marketing" before other
generic companies will <span CLASS="page_no" data-cite="2012 bl 94728 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> be approved by the FDA to enter the market. See
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(iv)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(5)(B)(iv). The 180-day period is not impacted by the NDA
filer's decision not to sue a subsequent ANDA filer on patents listed in the
subsequent filer's paragraph IV certifications.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Before the 2003 amendments to the Hatch-Waxman Act, the first generic
filer's 180-day exclusivity period was triggered by either its "first
commercial marketing" or a court judgment "holding the patent which is the
subject of the certification to be invalid or not infringed."
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(iv)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(5)(B)(iv) (2000). Under the 2003 amendments, the
exclusivity period is only triggered by the first-filing generic's first
commercial marketing, but the exclusivity period can be forfeited under
certain conditions, including failure to launch after a final court judgment
of non-infringement or invalidity. <i>See</i>Medicare Prescription Drug,
Improvement, and Modernization Act of 2003 ("MMA"), Pub.L. No. <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=USACTS%20108-173&amp;summary=yes#jcite">108-173</a>, <cite>&sect;
1102</cite>, 117 Stat.2066, 2457-60. For example, if a second ANDA filer obtained a
final judgment that the patents were invalid or not infringed, then the
first ANDA filer would forfeit its 180-day exclusivity period if it did not
market the drug within 75 days. See <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(D)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(5)(D). This change
in the statutory trigger makes no difference to the issues in this case, and
for simplicity we refer to a final judgment that triggers the 75-day
countdown to forfeiture of the exclusivity period as a "trigger" of the
180-day exclusivity period.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Also before the 2003 amendments, "NDA holders employed several methods of
delaying the early resolution of patent disputes." <i>Janssen Pharmaceutica,</i>
<i>N.V. v. Apotex, Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1AJ6V8N?jcsearch=540%20f%203d%201353&amp;summary=yes#jcite">540 F.3d 1353</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1AJ6V8N?jcsearch=540%20f%203d%201353&amp;summary=yes#jcite">1357</a> (Fed. Cir.2008). "For example, the
brand drug company might have several patents listed in the . . . Orange
Book with respect to a particular drug. It could be in the company's
interest to bring suit within 45 days on one patent and to hold the others
in reserve." <i>Teva Pharms. USA, Inc. v. Novartis Pharms. Corp.</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X16J406003?jcsearch=482%20f%203d%201330&amp;summary=yes#jcite">482 F.3d 1330</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X16J406003?jcsearch=482%20f%203d%201330&amp;summary=yes#jcite">1343-44</a> (Fed.Cir.2007) (quoting 149 Cong. Kec. 31,784 (2003)
(statement of Sen. Edward Kennedy)). The benefits of this strategy were
noted in the legislative history, including the threat of an infringement
suit on the reserved patent against the first ANDA filer after it secured
FDA approval, and the ability to delay triggering the first ANDA filer's
exclusivity period by preventing adjudication of noninfringement or
invalidity of the reserved patent. See 149 Cong. Kec. 31,784.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To address this problem, Congress specified that an ANDA filer who is not
sued within 45 days could bring a declaratory judgment action under
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEINES003?jcsearch=28%20U.S.C.%20%202201&amp;summary=yes#jcite">28 U.S.C. &sect; 2201</a> against the NDA holder, see <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(C)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(5)(C), and
that the federal courts would have declaratory judgment jurisdiction "to the
extent consistent with the Constitution," <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(5)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(5). Under this
amended Hatch-Waxman frame-work, if the first ANDA filer "parked" its
180-day exclusivity under an agreement with the brandname company, a
subsequent ANDA filer could independently trigger the first filer's
exclusivity period through a declaratory judgment action leading to a final
judgment of invalidity or
<span CLASS="page_no" data-cite="677 f 3d 1161" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1161" data-primary-citation="677 F.3d 1158">[*1161]</span> 
noninfringement, thereby accelerating the second ANDA filer's ability to
market its drug.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>II</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This case involves <span CLASS="page_no" data-cite="2012 bl 94728 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> such a declaratory judgment claim by the second ANDA
filer (Dey) against the patent holder and NDA filer (Sunovion), designed to
trigger the first <span CLASS="page_no" data-cite="102 uspq 2d 1713" data-cite-type="ReporterOfDecisions" data-cite-pageno="1713" data-primary-citation="102 U.S.P.Q.2d 1710">[**1713]</span> ANDA filer's (Breath's) exclusivity period. The FDA
approved Sunovion's NDA 20-837 for Xopenex in 1999. Sunovion listed three
patents relating to Xopenex in the Orange Book: <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=U.S.%20Patent%20No.%205,362,755&amp;summary=yes#jcite">U.S. Patent No. 5,362,755</a>
("the '<cite>755 patent</cite>"), <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=U.S.%20Patent%20No.%205,547,994&amp;summary=yes#jcite">U.S. Patent No. 5,547,994</a> ("the '<cite>994 patent</cite>"), and the
'<cite>289 patent</cite>.<a HREF="#fn300" name="fnref_fn300">[fn3]</a> The '<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=usp%205362755&amp;summary=yes#jcite">755 patent</a> expires on March 25, 2013; the '<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=usp%205547994&amp;summary=yes#jcite">994 patent</a>
expires on August 20, 2013; and the '<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=usp%206451289&amp;summary=yes#jcite">289 patent</a> expires on March 21, 2021.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In June 2005, Breath filed the first ANDA for generic Xopenex, which
contained paragraph IV certifications for all three patents. In October
2005, Sunovion sued Breath for infringement of all three patents in a case
that was transferred to the U.S. District Court for the District of
Massachusetts. In May 2008, the suit was dismissed based on a settlement
agreement between Sunovion and Breath. <i>Sepracor Inc. v. Breath Ltd.</i>, <cite>No.
06-10043</cite> (D.Mass. May 1, 2008). Under the settlement, Breath, by paying a
license fee, may sell generic Xopenex under its ANDA starting on August 20,
2012 (or on the date of an earlier third-party commercial launch). <i>See</i>J.A.
187-88.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In July 2005, Dey filed a second ANDA for generic Xopenex, which also
contained paragraph IV certifications for all three Orange Book patents. In
February 2006, Sunovion sued Dey over two of the patents in the District
Court for the District of Delaware, but Sunovion did not assert the '<cite>289
patent</cite>. Dey later filed a different ANDA on a "concentrate" version of
Xopenex, and after Sunovion again sued Dey with respect to the two patents
but not the '<cite>289 patent</cite>, the actions were consolidated in district court in
December 2006. On June 20, 2008, Dey brought this declaratory judgment
action, seeking a declaration that the '<cite>289 patent</cite> is invalid or not
in-fringed by either ANDA product. In response, Sunovion provided Dey with a
covenant not to sue on the '<cite>289 patent</cite> and moved to dismiss the declaratory
judgment action for lack of subject-matter jurisdiction.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On January 30, 2009, the district court denied Sunovion's motion to
dismiss in a thorough and well-reasoned opinion. <i>Dey</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1AGEJ0003?jcsearch=595%20f%20supp%202d%20355&amp;summary=yes#jcite">595 F.Supp.2d at 362-63</a>. In accordance with our precedent, the court held
that the covenant not to sue did not defeat declaratory judgment
jurisdiction. <i>See </i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1AGEJ0003?jcsearch=595%20F.%20Supp.%202d%20355&amp;summary=yes#jcite">id.at 360</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1AGEJ0003?jcsearch=362&amp;summary=yes#jcite">362</a>. The court also agreed with Dey that even
if it invalidated the two Orange Book patents asserted by Sunovion, the '<cite>289
patent</cite> would remain a legal barrier to its ANDA approval, and that this
potential barrier was a cognizable injury that could be redressed through
the declaratory judgment action under our decisions in <i>Caraco</i>and <i>Janssen</i>,
discussed below. <i>See </i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1AGEJ0003?jcsearch=595%20F.%20Supp.%202d%20355&amp;summary=yes#jcite">id.at 358-62</a> (citing <i>Caraco Pharm. Labs., Ltd. v.</i>
<i>Forest Labs., Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N7CE003?jcsearch=527%20f%203d%201278&amp;summary=yes#jcite">527 F.3d 1278</a> (Fed.Cir.2008); <i>Janssen</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1AJ6V8N?jcsearch=540%20f%203d%201353&amp;summary=yes#jcite">540 F.3d 1353</a>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Pursuant to a stipulation of the parties, the district court entered a
final judgment of noninfringement on June 20, 2011. <i>Dey Pharma, L.P. v.</i>
<i>Sunovion Pharms. Inc.</i>, <cite>No. 08-372</cite> (D.Del. June 20, 2011). Sunovion timely
appealed solely on jurisdictional grounds. This court has jurisdiction
<span CLASS="page_no" data-cite="677 f 3d 1162" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1162" data-primary-citation="677 F.3d 1158">[*1162]</span> 
over the appeal under <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEIMUG003?jcsearch=28%20U.S.C.%20%201295(a)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1295</a>(a)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Sunovion's Delaware suit against Dey <span CLASS="page_no" data-cite="2012 bl 94728 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> over the '<cite>755</cite> and '<cite>994</cite> patents is
still pending. On February 14, 2012, the district court entered judgment
following a jury verdict in favor of Sunovion on the infringement and
invalidity claims. <i>See Sunovion Pharms. Inc. v. Dey Pharma, L.P.</i>, <cite>No. 06-113</cite>
(D.Del. Feb. 14, 2012), ECF No. 581. The district court is currently
considering post-trial motions.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Whether an "actual controversy" exists that is sufficient to sustain
federal jurisdiction under the Declaratory Judgment Act,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEINES003?jcsearch=28%20U.S.C.%20%202201(a)&amp;summary=yes#jcite">28 U.S.C. &sect; 2201</a>(a), is a question of law that we review de novo. <i>Teva v.</i>
<i>Novartis</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X16J406003?jcsearch=482%20f%203d%201330&amp;summary=yes#jcite">482 F.3d at 1336</a>. In the Hatch-Waxman context, Congress extended
declaratory judgment jurisdiction to ANDA paragraph IV disputes,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(C)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(5)(C), and has directed federal courts to exercise
jurisdiction over these disputes "to the extent consistent with the
Constitution," <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(5)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(5). Under the Supreme Court's decision in
<i>Med-Immune, Inc. v. Genentech, Inc.</i>, declaratory judgment jurisdiction is
created when "the facts alleged, under all the circumstances, show that
there is a substantial controversy, between parties having adverse legal
interests, of sufficient immediacy and reality to warrant the issuance of a
declaratory judgment." <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">549 U.S. 118</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">127</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRI92FQNB5G0?jcsearch=127%20supreme%20court%20764&amp;summary=yes#jcite">127 S.Ct. 764</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRI92FQNB5G0?jcsearch=166%20l%20ed%202d%20604&amp;summary=yes#jcite">166 L.Ed.2d 604</a>
(<span CLASS="page_no" data-cite="102 uspq 2d 1714" data-cite-type="ReporterOfDecisions" data-cite-pageno="1714" data-primary-citation="102 U.S.P.Q.2d 1710">[**1714]</span> 2007) (quoting <i>Md. Cas. Co. v. Pac. Coal &amp; Oil Co.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C07D?jcsearch=312%20us%20270&amp;summary=yes#jcite">312 U.S. 270</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C07D?jcsearch=312%20us%20270&amp;summary=yes#jcite">273</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C07D?jcsearch=61%20supreme%20court%20510&amp;summary=yes#jcite">61 S.Ct. 510</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C07D?jcsearch=85%20l%20ed%20826&amp;summary=yes#jcite">85 L.Ed. 826</a> (1941)) (internal quotation mark omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In a number of past cases we have considered the scope of declaratory
jurisdiction in this context. Most pertinent are our decisions in <i>Caraco</i>and
<i>Janssen.</i>In <i>Caraco</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N7CE003?jcsearch=527%20f%203d%201278&amp;summary=yes#jcite">527 F.3d at 1286</a>, the patents listed in the Orange Book
were <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=usp%20re34712&amp;summary=yes#jcite">U.S. Patent No. RE34,712</a> ("the '<cite>712 patent</cite>"), which expired in 2012,
and <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=usp%206916941&amp;summary=yes#jcite">U.S. Patent No. 6,916,941</a> ("the '<cite>941 patent</cite>"), which expires in 2023.
The first ANDA filer (Ivax) was entitled to launch upon the expiration of
the '<cite>712 patent</cite>.<a HREF="#fn400" name="fnref_fn400">[fn4]</a> The NDA holder (Forest) sued the second ANDA filer
(Caraco) for infringement of the '<cite>712 patent</cite>. <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N7CE003?jcsearch=527%20F.3d%201278&amp;summary=yes#jcite">Id.at 1288</a>. Caraco then
brought a declaratory judgment action over the later-expiring '<cite>941 patent</cite>.
<i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N7CE003?jcsearch=527%20F.3d%201278&amp;summary=yes#jcite">Id</a>.</i>To trigger the first ANDA filer's 180-day exclusivity, the court
concluded that Caraco would have needed to succeed in both the declaratory
judgment action over the '<cite>941 patent</cite> and the separate infringement suit over
the '<cite>712 patent</cite>. <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N7CE003?jcsearch=527%20F.3d%201278&amp;summary=yes#jcite">Id.at 1287</a>. We held there was declaratory jurisdiction
because the NDA holder's actions were "potentially exclud[ing]
non-infringing generic drugs from the market." <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N7CE003?jcsearch=527%20F.3d%201278&amp;summary=yes#jcite">Id.at 1292</a>. We also held that
the declaratory judgment action was not mooted by Forest's covenant not to
sue Caraco over the '<cite>941 patent</cite> because only a court judgment of
noninfringement or invalidity would trigger Ivax's exclusivity period and
accelerate Caraco's market entry. <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N7CE003?jcsearch=527%20F.3d%201278&amp;summary=yes#jcite">Id.at 1297</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Janssen</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X19GM76003?jcsearch=540%20f%203d%201353&amp;summary=yes#jcite">540 F.3d at 1357-58</a>, the patents listed in the Orange Book
were <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=usp%204804663&amp;summary=yes#jcite">U.S. Patent No. 4,804,663</a> ("the '<cite>663 patent</cite>"), which expired in 2008,
and <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=U.S.%20Patent%20Nos.%205,453,425&amp;summary=yes#jcite">U.S. Patent Nos. 5,453,425</a> <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=and%205,%20616,587&amp;summary=yes#jcite">and 5, 616,587</a> ("the '<cite>425</cite> and '<cite>587</cite> patents"),
which
<span CLASS="page_no" data-cite="677 f 3d 1163" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1163" data-primary-citation="677 F.3d 1158">[*1163]</span> 
both expire in 2014. The first ANDA filer (Teva) was entitled to launch upon
the expiration of the '<cite>663 patent</cite>.<a HREF="#fn500" name="fnref_fn500">[fn5]</a> The NDA holder (Janssen) sued the
second ANDA filer (Apotex) for infringement of the '<cite>663 patent</cite>. <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X19GM76003?jcsearch=540%20F.3d%201353&amp;summary=yes#jcite">Id.at 1358</a>.
Apotex then asserted declaratory judgment counterclaims over the
later-expiring '<cite>425</cite> and '<cite>587</cite> patents. <i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X19GM76003?jcsearch=540%20F.3d%201353&amp;summary=yes#jcite">Id</a>.</i>We held that there would have been
declaratory judgment <span CLASS="page_no" data-cite="2012 bl 94728 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> jurisdiction under <i>Caraco</i>, except that Apotex
stipulated to the validity, infringement, and enforceability of the '<cite>663
patent</cite>. <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X19GM76003?jcsearch=540%20F.3d%201353&amp;summary=yes#jcite">Id.at 1360</a>. Thus, unlike in <i>Caraco</i>, there was no immediate
controversy: Apotex's success on the '<cite>425</cite> and '<cite>587</cite> patents would not trigger
Teva's 180-day exclusivity period. <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X19GM76003?jcsearch=540%20F.3d%201353&amp;summary=yes#jcite">Id.at 1361</a>. And once the '<cite>663 patent</cite>
expired in 2008, Teva was entitled to launch, so Apotex would only be
"excluded from the market by Teva's 180-day exclusivity period &mdash; a period to
which Teva is entitled to under the Hatch-Waxman Act." <i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X19GM76003?jcsearch=540%20F.3d%201353&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914970" href="#headnote_pq2-dec_914970">[1]</a> We first address the question whether, under our decisions in <i>Caraco</i>and
<i>Janssen</i>, declaratory judgment jurisdiction existed when Dey first brought
this action on June 20, 2008. We agree with the district court that Dey has
done "nothing equivalent to Apotex's stipulation to the infringement and
validity of the [first-expiring] patent [in <i>Janssen</i>]." <i>Dey</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1AGEJ0003?jcsearch=595%20f%20supp%202d%20355&amp;summary=yes#jcite">595 F.Supp.2d at 362</a>. Just as in <i>Caraco</i>, the second ANDA filer (Dey) brought
a declaratory judgment action over the last-expiring Orange Book patent (the
'<cite>289 patent</cite>) after the NDA holder (Sunovion) only sued for infringement of
the other Orange Book patents (the '<cite>755</cite> and '<cite>994</cite> patents). And like the
second ANDA filer in <i>Caraco</i>, Dey "alleges it is being excluded from selling
a non-infringing product," and this injury is "fairly traceable" to Sunovion
and "redressible by a declaratory judgment that the ['289 patent] is not
infringed." <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N7CE003?jcsearch=527%20f%203d%201278&amp;summary=yes#jcite">527 F.3d at 1291-93</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As Sunovion conceded at argument, its only argument against finding that
declaratory jurisdiction existed in June 2008 is that success in the
declaratory judgment action alone is insufficient to redress Dey's injury
because Dey would still need to succeed in the separate infringement
litigation over the other Orange Book patents. <i>See</i>Oral Argument at
30:52-31:28. But this was also true in <i>Caraco.</i>We concluded that "only a
judgment of invalidity or noninfringement with respect to <i>both</i>the '<cite>712</cite> and
'<cite>941</cite> patents can trigger [the first ANDA filer's] exclusivity period."
<i>Caraco<span CLASS="page_no" data-cite="102 uspq 2d 1715" data-cite-type="ReporterOfDecisions" data-cite-pageno="1715" data-primary-citation="102 U.S.P.Q.2d 1710">[**1715]</span> </i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N7CE003?jcsearch=527%20f%203d%201278&amp;summary=yes#jcite">527 F.3d at 1295</a> (emphasis added).<a HREF="#fn600" name="fnref_fn600">[fn6]</a> We further explained the
redressibility element:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      If Caraco obtains a favorable judgment [in its declaratory
    judgment action], then it will only need a judgment of invalidity or
    noninfringement on [the other Orange Book patent] in order to
    activate [the first ANDA filer's] exclusivity period and obtain FDA
    approval as swiftly as possible. Thus, a favorable judgment in this
    action would eliminate
<span CLASS="page_no" data-cite="677 f 3d 1164" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1164" data-primary-citation="677 F.3d 1158">[*1164]</span> 
    the potential for the [declaratory judgment] patent to exclude
    Caraco from the drug market.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N7CE003?jcsearch=527%20F.3d%201278&amp;summary=yes#jcite">Id.at 1293</a>. Similarly, a favorable declaratory judgment for Dey on the
'<cite>289 patent</cite> will eliminate the potential for that patent to exclude Dey from
the market, and Dey would then only need a judgment of invalidity or
noninfringement on the other Orange Book patents to trigger Breath's
exclusivity period.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under Sunovion's logic, if the Orange Book patents were divided between
two declaratory judgment actions, then each case would preclude a finding of
jurisdiction in the other. But the only reason there are two cases here is
that Sunovion declined to sue Dey on all the Orange Book patents, and <span CLASS="page_no" data-cite="2012 bl 94728 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> there
is no reason to deny jurisdiction over the second action until the initial
litigation has been resolved. As we held under materially identical facts in
<i>Caraco</i>, simply eliminating one barrier is sufficient for declaratory
jurisdiction, so long as litigation is also pending that could eliminate the
other barriers. <i>See</i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N7CE003?jcsearch=527%20F.3d%20at%201293&amp;summary=yes#jcite">527 F.3d at 1293</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  III
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Having concluded that jurisdiction existed when Dey filed its declaratory
judgment action in June 2008, we turn to Sunovion's argument that
jurisdiction no longer exists. Sunovion does not attempt to argue that its
covenant not to sue Dey over the '<cite>289 patent</cite> moots this case, as that
argument is foreclosed by our contrary holding in <i>Caraco. See</i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N7CE003?jcsearch=527%20F.3d%20at%201297&amp;summary=yes#jcite">527 F.3d at
1297</a>. Rather, Sunovion's argument has two parts: (1) It urges that as a
practical matter, the separate litigation over the <cite>'755</cite> and <cite>'994</cite> patents
cannot be concluded by a final judgment before Breath is entitled to launch
its generic product on August 20, 2012;<a HREF="#fn700" name="fnref_fn700">[fn7]</a> the final resolution of that
litigation is necessary to trigger Breath's exclusivity period. (2) Sunovion
further argues that once Breath is entitled to launch its generic product,
there will no longer be a case or controversy necessary to support
declaratory judgment jurisdiction. In other words, Sunovion argues that
under the <i>Medlmmune</i>"all the circumstances" test, the court should not allow
a declaratory action challenging <i>any</i>Orange Book patent to proceed unless
<i>all</i>actions challenging the Orange Book patents can be completed before the
date of potential generic entry will arrive and, in Sunovion's view, deprive
the district court of jurisdiction.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914971" href="#headnote_pq2-dec_914971">[2]</a> The problem with Sunovion's view is that its last assumption is incorrect.
The district court will not lose jurisdiction simply because the period of
possible first generic market entry arrives. Even after Breath is entitled
to launch, the possibility remains that Breath will not do so. Breath has
not announced plans to launch on August 20, and it is well known that the
first generic often elects to delay entry for various reasons, including
possible payments from the brand-name manufacturer to delay the launch. In
the debate leading up to the 2003 Hatch-Waxman amendments, Congress was
concerned by the Federal Trade Commission ("FTC") report
<span CLASS="page_no" data-cite="677 f 3d 1165" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1165" data-primary-citation="677 F.3d 1158">[*1165]</span> 
that "the [180-day] exclusivity has at times been parked through collusive
agreements between brand and generic companies." 149 Cong. Rec. 31,783
(2003) (statement of Sen. Edward Kennedy). For example, brand-name companies
were alleged to have paid the first generic filer to not enter the market.
Fed. Trade Comm'n, <i>Genetic Drug Entry Prior to <span CLASS="page_no" data-cite="102 uspq 2d 1716" data-cite-type="ReporterOfDecisions" data-cite-pageno="1716" data-primary-citation="102 U.S.P.Q.2d 1710">[**1716]</span> Patent Expiration</i>, at
vii-viii (2002).<a HREF="#fn800" name="fnref_fn800">[fn8]</a> Indeed, it is that very concern that in part led
Congress to enact the forfeiture provisions of the 2003 amendments, which
were discussed earlier. <i>See</i>MMA &sect; 1102. While those forfeiture provisions are
not directly applicable here unless there is a judgment of noninfringement
or invalidity on all Orange Book patents, the forfeiture legislation
confirms that the first generic entry may often be delayed. <i>See also<span CLASS="page_no" data-cite="2012 bl 94728 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> </i>C. Scott
Hemphill, <i>An Aggregate Approach to Antitrust: Using New Data and Rulemaking</i>
<i>To Preserve Drug Competition</i>, 109 Colum. `L.Rev. 629, 646-47 (2009) (finding
that 60 out of 143 Hatch-Waxman settlements between 1984 and 2008 involved
delayed generic entry and some form of payment from the brand-name company
to the generic). If Breath chooses to delay triggering its 180-day
exclusivity period, Dey and other generics could potentially be kept off the
market until the expiration of the <cite>'289</cite> patent in 2021, absent a judgment of
non-infringement or invalidity.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Sunovion urges, however, that we held in <i>Janssen</i>that "a possible delay in
the future of a first Paragraph IV ANDA filer in launching its generic
product does not give rise to declaratory judgment jurisdiction."
Appellant's Br. 34 (quoting <i>Janssen</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X19GM76003?jcsearch=540%20f%203d%201353&amp;summary=yes#jcite">540 F.3d at 1363</a>). What Sunovion
ignores is that there is a difference between finding that a controversy
exists to initiate a suit and determining that the controversy has become
moot. While Article III requires that "an actual controversy must be extant
at all stages of review, not merely at the time the complaint is filed," the
question of whether a controversy exists at a later stage of the proceeding
is governed by mootness doctrine. <i>Arizonans for Official English v. Arizona</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CCTT?jcsearch=520%20us%2043&amp;summary=yes#jcite">520 U.S. 43</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CCTT?jcsearch=520%20us%2043&amp;summary=yes#jcite">67</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CCTT?jcsearch=117%20supreme%20court%201055&amp;summary=yes#jcite">117 S.Ct. 1055</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CCTT?jcsearch=137%20l%20ed%202d%20170&amp;summary=yes#jcite">137 L.Ed.2d 170</a> (1997) (quoting <i>Preiser v.</i>
<i>Newkirk</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C917?jcsearch=422%20us%20395&amp;summary=yes#jcite">422 U.S. 395</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C917?jcsearch=422%20us%20395&amp;summary=yes#jcite">401</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C917?jcsearch=95%20supreme%20court%202330&amp;summary=yes#jcite">95 S.Ct. 2330</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C917?jcsearch=45%20l%20ed%202d%20272&amp;summary=yes#jcite">45 L.Ed.2d 272</a> (1975)). As the
Supreme Court explained in <i>Cardinal Chemical Co. v. Morton International,</i>
<i>Inc.</i>:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      [W]hile the initial burden of establishing the trial court's
    jurisdiction rests on the party invoking that jurisdiction, once
    that burden has been met courts are entitled to presume, absent
    further information, that jurisdiction continues. If a party to an
    appeal suggests that the controversy has, since the rendering of
    judgment below, become moot, that party bears the burden of coming
    forward with the subsequent events that have produced that alleged
    result.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CCBB?jcsearch=508%20us%2083&amp;summary=yes#jcite">508 U.S. 83</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CCBB?jcsearch=508%20us%2083&amp;summary=yes#jcite">98</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CCBB?jcsearch=113%20supreme%20court%201967&amp;summary=yes#jcite">113 S.Ct. 1967</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CCBB?jcsearch=124%20l%20ed%202d%201&amp;summary=yes#jcite">124 L.Ed.2d 1</a> (1993). As we noted in
<i>Benitec Australia, Ltd. v. Nucleonics, Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X17ATMK003?jcsearch=495%20f%203d%201340&amp;summary=yes#jcite">495 F.3d 1340</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X17ATMK003?jcsearch=495%20f%203d%201340&amp;summary=yes#jcite">1345</a>
(Fed.Cir.2007), <i>Cardinal Chemical</i>requires that the party arguing that a case
has become moot bears "[t]he
<span CLASS="page_no" data-cite="677 f 3d 1166" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1166" data-primary-citation="677 F.3d 1158">[*1166]</span> 
burden of bringing forth such further information" of mootness. "The `heavy
burden of persua[ding]' the court" that a case is moot "lies with the party
asserting mootness." <i>Friends of the Earth, Inc. v. Laidlaw Envtl. Servs.</i>
<i>(TOC), Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2TNEQ?jcsearch=528%20us%20167&amp;summary=yes#jcite">528 U.S. 167</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2TNEQ?jcsearch=528%20us%20167&amp;summary=yes#jcite">189</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2TNEQ?jcsearch=120%20supreme%20court%20693&amp;summary=yes#jcite">120 S.Ct 693</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2TNEQ?jcsearch=145%20l%20ed%202d%20610&amp;summary=yes#jcite">145 L.Ed.2d 610</a> (2000)
(quoting <i>United States v. Concentrated Phosphate Exp. Ass'n</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C7AB?jcsearch=393%20us%20199&amp;summary=yes#jcite">393 U.S. 199</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C7AB?jcsearch=393%20us%20199&amp;summary=yes#jcite">203</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C7AB?jcsearch=89%20supreme%20court%20361&amp;summary=yes#jcite">89 S.Ct. 361</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C7AB?jcsearch=21%20l%20ed%202d%20344&amp;summary=yes#jcite">21 L.Ed.2d 344</a> (1968)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We conclude that Sunovion has not met this burden. Indeed, Sunovion
conceded at argument that this case will not be moot until Breath actually
goes on the market in a way that would trigger its 180-day exclusivity
period. <i>See</i>Oral Argument at 10:50; <i>see also Eisai Co. v. Teva Pharms. USA,</i>
<i>Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FIJ86003?jcsearch=180%20L.Ed.2d%20818&amp;summary=yes#jcite">___ U.S. ___</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FIJ86003?jcsearch=131%20supreme%20court%202991&amp;summary=yes#jcite">131 S.Ct. 2991</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FIJ86003?jcsearch=180%20l%20ed%202d%20818&amp;summary=yes#jcite">180 L.Ed.2d 818</a> (2011) (remanding a case
with instructions to dismiss as moot where the first ANDA filer launched
prior to a final judgment in the second ANDA's declaratory judgment action).
It is uncontested that Breath has not yet marketed generic Xopenex, and that
its failure to do so, absent a triggering event, could delay Dey's ability
to market until 2021, when the '<cite>289 patent</cite> expires. Since there was
jurisdiction when Dey filed this declaratory judgment action in June 2008,
this case <span CLASS="page_no" data-cite="2012 bl 94728 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> may proceed until rendered moot. We affirm the district court's
judgment of non-infringement.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  COSTS
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Costs to appelles.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> Sunovion was formerly known as Sepracor.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> The filing of the ANDA is treated as an act of infringement. <i>See</i>35
U.S.C. &sect; 271(e)(2).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> Three other patents, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=U.S.%20Patent%20Nos.%205,760,090&amp;summary=yes#jcite">U.S. Patent Nos. 5,760,090</a><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=,%205,844,002&amp;summary=yes#jcite">, 5,844,002</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=and%206,%20083,993&amp;summary=yes#jcite">and 6,
083,993</a>, were also listed, but they have expired and are not pertinent here.
For simplicity we omit them from the description of the litigation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> The NDA holder only sued Ivax for infringement of the '<cite>712 patent</cite>, and
we affirmed a judgment that the patent was valid and infringed. <i>See Forest</i>
<i>Labs., Inc. v. Ivax Pharms., Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X17JKLU003?jcsearch=501%20f%203d%201263&amp;summary=yes#jcite">501 F.3d 1263</a> (Fed.Cir.2007). Because the
NDA holder did not sue over the '<cite>941 patent</cite>, the FDA could approve Ivax's
ANDA upon the expiration of the '<cite>712 patent</cite>. <i>See Caraco</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N7CE003?jcsearch=527%20f%203d%201278&amp;summary=yes#jcite">527 F.3d at 1287</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> Teva filed a paragraph III certification for the '<cite>663 patent</cite> and was
not sued over the '425 and '587 patents (for which it filed paragraph IV
certifications), so the FDA would approve Teva's ANDA upon the expiration of
the '<cite>663 patent</cite>. <i>See </i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X19GM76003?jcsearch=540%20F.3d%201353&amp;summary=yes#jcite">id.at 1358</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> Sunovion argues that <i>Caraco</i>is distinguishable because Caraco, in fact,
could have triggered Ivax's exclusivity period with a final judgment on the
'<cite>941 patent</cite> in its declaratory judgment action (because Ivax enjoyed
exclusivity only with respect to the '<cite>941 patent</cite>), and that the '<cite>712 patent</cite>
challenge was thus immaterial. <i>See</i>Appellant's Br. 23. But our decision in
<i>Caraco</i>did not rest on this ground. We assumed that success was required for
both patents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> Under its settlement with Sunovion, Breath may launch generic Xopenex
on August 20, 2012, which would trigger its exclusivity period and allow Dey
to launch its product 180 days later. Sunovion urges that the correct date
is actually June 6, 2012, which is 75 days before the August 20 date. It
urges that to cause Breath to forfeit its exclusivity under
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(D)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(5)(D), Dey must obtain a final judgment on all Orange
Book patents more than 75 days before Breath may launch on August 20; i.e.,
by June 6, 2012. Whether the correct date is August 20 or June 6 makes no
difference for purposes of the legal issues involved here.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> The 2002 FTC report also noted that under some settlement agreements,
the "generic was marketing the brand-name company's product as a generic,"
rather than "under its own ANDA." <i><cite>Id</cite>.</i>at vii. In this case. Breath and
Sunovion have entered into a separate supply agreement, under which Breath
could purchase Xopenex from Sunovion on a cost-plus-margin basis to sell
under Sunovion's NDA, also effective August 20, 2012. <i>See</i>J.A. 132, 507. We
do not decide whether this would necessarily be "commercial marketing" that
triggers the 180-day exclusivity under <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(iv)(I)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(5)(B)(iv)(I). We
also note that because no discovery has been allowed in this case, it is
unclear whether Breath has incentives to delay triggering its 180-day
exclusivity period.
</p></div>
</div>
<!--BBLS DD 1699956064259-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HF6KE003/history">Direct History (10)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HF6KE003/analysis">Case Analysis (2)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HF6KE003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
2
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Pharmaceuticals</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1Q6M003AO82">11-01507 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Copyright Law</div><div class='facetItemLabel'>Damages &amp; Remedies</div><div class='facetItemLabel'>Patent Law</div><div class='facetItemLabel'>Trademark Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "8aa6afcb6c93e1fd566e4a7344efbc84";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY26fd63&previousPageId=&previousActivityInstanceId=ENTITY29fddf&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:45:44-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HF6KE003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY29fddf&previousPageId=&previousActivityInstanceId=ENTITYe74322&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:45:42-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1HF6KE003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HF6KE003";
$('#page_loader').show().spin();
JUDGE_IDS=["15753020","3027440","3408847"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
